{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:40:15Z","timestamp":1737052815939,"version":"3.33.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[1999,1]]},"DOI":"10.1007\/s11906-999-0077-7","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T15:57:35Z","timestamp":1180108655000},"page":"79-87","source":"Crossref","is-referenced-by-count":9,"title":["Endothelin in cardiovascular control: The role of endothelin antagonists"],"prefix":"10.1007","volume":"1","author":[{"given":"Ren\u00e9 R.","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Czyborra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"77_CR1","first-page":"57","volume-title":"Calcium Antagonists in Clinical Medicine","author":"RR Wenzel","year":"1998","unstructured":"Wenzel RR, Noll G, L\u00fcscher TF: Endothelial regulation of vascular tone and growth: role of calcium antagonists. In Calcium Antagonists in Clinical Medicine, 2nd ed. Edited by Epstein M. Philadelphia: Hanley & Belfus; 1998:57\u201380.","edition":"2nd ed."},{"key":"77_CR2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/348730a0","volume":"348","author":"H Arai","year":"1990","unstructured":"Arai H, Hori S, Aramori I, et al.: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730\u2013732.","journal-title":"Nature"},{"key":"77_CR3","doi-asserted-by":"crossref","first-page":"19126","DOI":"10.1016\/S0021-9258(17)46743-3","volume":"268","author":"S Karne","year":"1993","unstructured":"Karne S, Jayawickreme CK, Lerner MR: Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993, 268:19126\u201319133.","journal-title":"J Biol Chem"},{"key":"77_CR4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/348732a0","volume":"348","author":"T Sakurai","year":"1990","unstructured":"Sakurai T, Yanagisawa M, Takuwa Y, et al.: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732\u2013735.","journal-title":"Nature"},{"key":"77_CR5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0165-6147(92)90038-8","volume":"13","author":"T Sakurai","year":"1992","unstructured":"Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992, 13:103\u2013108.","journal-title":"Trends Pharmacol Sci"},{"key":"77_CR6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1476-5381.1987.tb11367.x","volume":"92","author":"MW Radomski","year":"1987","unstructured":"Radomski MW, Palmer RM, Moncada S: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987, 92:639\u2013646.","journal-title":"Br J Pharmacol"},{"key":"77_CR7","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/01.RES.68.6.1768","volume":"68","author":"CM Boulanger","year":"1991","unstructured":"Boulanger CM, L\u00fcscher TF: Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res 1991, 68:1768\u20131772.","journal-title":"Circ Res"},{"key":"77_CR8","first-page":"848","volume":"273","author":"CR Aversa","year":"1997","unstructured":"Aversa CR, Oparil S, Caro J, et al.: Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice Am J Physiol 1997, 273:848\u2013855.","journal-title":"Am J Physiol"},{"key":"77_CR9","first-page":"1260","volume":"263","author":"TS Elton","year":"1992","unstructured":"Elton TS, Oparil S, Taylor GR, et al.: Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992, 263:1260\u20131264.","journal-title":"Am J Physiol"},{"key":"77_CR10","first-page":"359","volume":"90","author":"S Goerre","year":"1994","unstructured":"Goerre S, Wenk M, B\u00e4rtsch P, et al.: Endothelin-1 in pulmonary Hypertension associated with high altitude Circulation 1994, 90:359\u2013364.","journal-title":"Circulation"},{"key":"77_CR11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/01.HYP.23.5.581","volume":"23","author":"RR Wenzel","year":"1994","unstructured":"Wenzel RR, Noll G, L\u00fcscher TF: Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994, 23:581\u2013586.","journal-title":"Hypertension"},{"key":"77_CR12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.CIR.94.3.316","volume":"94","author":"RR Wenzel","year":"1996","unstructured":"Wenzel RR, Duthiers N, Noll G, et al.: Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 1996, 94:316\u2013322. This study for the first time shows the effects of an ET antagonist compared with a calcium channel blocker on endogenous and exogenous endothelin in the skin microcirculation of patients with severe atherosclerosis and angiographically documented CAD. Interestingly, a mixed antagonist iduced a significantly higher vasodilation that an ET(A) antagonist in CAD patients, but not in age-matched healthy volunteers.","journal-title":"Circulation"},{"key":"77_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ndt\/12.4.649","volume":"12","author":"RR Wenzel","year":"1997","unstructured":"Wenzel RR: Minimal invasive In vivo Pharmacology: news from a new method holding promise in nephrology-related research. Nephrol Dial Transplant 1997, 12:649\u2013651. This review gives a critical overview on minimal invasive pharmacologic methods in vivo in humans.","journal-title":"Nephrol Dial Transplant"},{"key":"77_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2125.1998.00703.x","volume":"45","author":"RR Wenzel","year":"1998","unstructured":"Wenzel RR, Zbinden S, Noll G, et al.: Endothelin-1 induced vasodilation in the human skin is mediated by nociceptor fibers and release of nitric oxide. Br J Clin Pharmacol 1998, 45:441\u2013446. This study shows for the first time in humans in vivo that endothelin-1 is a neurotransmitter and leads to neurogenic vasodilation mediated through the release of nitric oxide via ET(A) receptors.","journal-title":"Br J Clin Pharmacol"},{"key":"77_CR15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","volume":"344","author":"WG Haynes","year":"1994","unstructured":"Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852\u2013854.","journal-title":"Lancet"},{"key":"77_CR16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/01.CIR.83.2.469","volume":"83","author":"W Kiowski","year":"1991","unstructured":"Kiowski W, L\u00fcscher TF, Linder L, B\u00fchler FR: Endothelin-1-induced vasoconstriction in humans: reversal by calciu channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991, 83:469\u2013475.","journal-title":"Circulation"},{"key":"77_CR17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/39724","volume":"389","author":"DE Clapham","year":"1997","unstructured":"Clapham DE, Ferro CJ, Haynes WG, et al.: The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction. Nature 1997, 389:783\u2013784. This study investigated systemic administration of ET antagonists in healthy volunteers. Vasoconstriction of local administration of ET-1 was attenuated 12 hours after systemic infusion of an ET(A) antagonist.","journal-title":"Nature"},{"key":"77_CR18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/01.CIR.81.4.1415","volume":"81","author":"H Vierhapper","year":"1990","unstructured":"Vierhapper H, Wagner O, Nowotny P, Waldhausl W: Effect of endothelin-1 in man. Circulation 1990, 81:1415\u20131418.","journal-title":"Circulation"},{"key":"77_CR19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ki.1994.284","volume":"46","author":"TJ Rabelink","year":"1994","unstructured":"Rabelink TJ, Kaasjager KA, Boer P, et al.: Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994, 46:376\u201381.","journal-title":"Kidney Int"},{"key":"77_CR20","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1097\/00005344-199800001-00044","volume":"31","author":"RN Willette","year":"1998","unstructured":"Willette RN, Sauermelch CF, Storer BL, et al.: Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors. J Cardiovasc Pharmacol 1998, 31:S149\u2013157.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.RES.72.1.20","volume":"72","author":"R Mosqueda-Garcia","year":"1993","unstructured":"Mosqueda-Garcia R, Inagami T, Appalsamy M, et al.: Endothelin as a neuropeptide. Cardiovascular effects in the brainstem of normotensive rats. Circ Res 1993, 72:20\u201335.","journal-title":"Circ Res"},{"key":"77_CR22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0022-3565(24)36581-4","volume":"281","author":"A Brizzolara-Gourdie","year":"1997","unstructured":"Brizzolara-Gourdie A, Webb JG: Angiotensin II potentiates vasodilation of rat aorta by cAMP elevating agonists. J Pharmacol Exp Ther 1997, 281:354\u2013359.","journal-title":"J Pharmacol Exp Ther"},{"key":"77_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1006\/pulp.1994.1048","volume":"7","author":"JE Nally","year":"1994","unstructured":"Nally JE, Clayton RA, Wakelam MJ, et al.: Angiotensin II enhances responses to endothelin-1 in bovine bronchial smooth muscle. Pulm Pharmacol 1994, 7:409\u2013413.","journal-title":"Pulm Pharmacol"},{"key":"77_CR24","doi-asserted-by":"crossref","first-page":"1304 1308","DOI":"10.1016\/0006-291X(89)92252-3","volume":"159","author":"Y Tabuchi","year":"1989","unstructured":"Tabuchi Y, Nakamaru M, Rakugi H, et al.: Endothelin enhances adrenergic vasoconstriction in perfused rat mesenteric arteries. Biochem Biophys Res Commun 1989, 159:1304 1308.","journal-title":"Biochem Biophys Res Commun"},{"key":"77_CR25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1476-5381.1990.tb14110.x","volume":"100","author":"Y Dohi","year":"1990","unstructured":"Dohi Y, L\u00fcscher TF: Aging differentially affects direct and indirect actions of endothelin-1 in perfused mesenteric arteries of the rat. Br J Pharmacol 1990, 100:889\u2013893.","journal-title":"Br J Pharmacol"},{"key":"77_CR26","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.96.5.1593","volume":"96","author":"P Moreau","year":"1997","unstructured":"Moreau P, d\u2019Uscio LV, Shaw S, et al.: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997, 96:1593\u20131597. The interaction of the renin-angiotensin system and ET is examined in this experimental study considering vascular structural changes and blood pressure, and a potential role of an ET(A) antagonist.","journal-title":"Circulation"},{"key":"77_CR27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF03401733","volume":"4","author":"N Ruiz-Opaz","year":"1998","unstructured":"Ruiz-Opaz N, Hirayama K, Akimoto K, Herrera VL: Molecular characterization of a dual endothelin-1\/ngiotensin II receptor. Mol Med 1998, 4:96\u2013108. A very interesting paper that identifies for the first time a molecular link between the ET-1\/angiotensin II hormonal systems that could underlie observed similar physiologic responses elicited by ET-1 and angiotensin II in different organ systems.","journal-title":"Mol Med"},{"key":"77_CR28","first-page":"162","volume":"10","author":"TF L\u00fcscher","year":"1995","unstructured":"L\u00fcscher TF, Wenzel RR: Endothelin in renal disease: role of endothelin antagonists. Nephrol Dial Transplant 1995, 10:162\u2013166.","journal-title":"Nephrol Dial Transplant"},{"key":"77_CR29","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0735-1097(97)00095-8","volume":"29","author":"RR Wenzel","year":"1997","unstructured":"Wenzel RR, Allegranza G, Binggeli C, et al.: Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: Role of pharmacokinetics. J Am Coll Cardiol 1997, 29:1607\u20131614. This study shows a marked activation of the sympathetic nervous system as assessed by microneurography with the calcium antagonist nifedipine independently from drug release formulation and a simulataneous increase in plasma endothelin only with the slow release drug formulation.","journal-title":"J Am Coll Cardiol"},{"key":"77_CR30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-642-79803-0_11","volume-title":"In The Endothelium in Cardiovascular Disease","author":"RR Wenzel","year":"1995","unstructured":"Wenzel RR, L\u00fcscher TF: Endothelin receptor antagonists as new tools to inhibit endothelin induced vasoconstriction in humans: comparison with calcium channel blockers. In In The Endothelium in Cardiovascular Disease. Edited by L\u00fcscher TF. Heidelberg: Springer-Verlag; 1995:129\u2013147."},{"key":"77_CR31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(24)37635-9","volume":"286","author":"EH Ohlstein","year":"1998","unstructured":"Ohlstein EH, Nambi P, Hay DW, et al.: Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther 1998, 286:650\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"77_CR32","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1097\/00005344-199322008-00099","volume":"22","author":"M Clozel","year":"1993","unstructured":"Clozel M, Breu V, Gray GA, Loffler BM: In vivo Pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993, 22:S377\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR33","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1073\/pnas.86.10.3915","volume":"86","author":"K Goto","year":"1989","unstructured":"Goto K, Kasuya Y, Matsuki N, et al.: Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca(2+) channel in vascular smooth muscle. Proc Natl Acad Sci U S A 1989, 86:3915\u20133918.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"77_CR34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/00005344-199010000-00019","volume":"16","author":"Z Yang","year":"1990","unstructured":"Yang Z, Bauer E, von SL, et al.: Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990, 16:654\u2013660.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1006\/bbrc.1994.2514","volume":"204","author":"MR Tschudi","year":"1994","unstructured":"Tschudi MR, L\u00fcscher TF: Characterization of contractile endothelin and angiotensin receptors in human arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Comm 1994, 204:685\u2013690.","journal-title":"Biochem Biophys Res Comm"},{"key":"77_CR36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/01.HYP.25.4.739","volume":"25","author":"H Takase","year":"1995","unstructured":"Takase H, Moreau P, L\u00fcscher TF: Endothelin receptor subtypes in small arteries: studies with FR139317 and bosentan. Hypertension 1995, 25:739\u2013743.","journal-title":"Hypertension"},{"key":"77_CR37","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1097\/00005344-199800001-00024","volume":"31","author":"LN Pierre","year":"1998","unstructured":"Pierre LN, Davenport AP: Relative contribution of endothelin A and endothelin B receptors to vasoconstriction in small arteries from human heart and brain. J Cardiovasc Pharmacol 1998, 31:S74\u2013876. The investigation of the relative contribution to vasoconstriction of ET(A) and ET(B) receptors in small human vessels provides further arguments for and against selective or nonselective receptor antagonism.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2125.1997.t01-1-00631.x","volume":"44","author":"JR Berrazueta","year":"1997","unstructured":"Berrazueta JR, Bhagat K, Vallance P, MacAllister RJ: Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 1997, 44:569\u2013571.","journal-title":"Br J Clin Pharmacol"},{"key":"77_CR39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(94)90217-8","volume":"265","author":"H Yamamura","year":"1994","unstructured":"Yamamura H, Nabe T, Kohno S, Ohata K: Endothelin-1, one of the most potent histamine releasers in mouse peritoneal mast cells. Eur J Pharmacol 265:9\u201315, 1994.","journal-title":"Eur J Pharmacol"},{"key":"77_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(94)90134-1","volume":"257","author":"H Yamamura","year":"1994","unstructured":"Yamamura H, Nabe T, Kohno S, Ohata K: Endothelin-1 induces release of histamine and leukotriene C4 from mouse bone marrow-derived mast cells. Eur J Pharmacol 1994, 257:235\u2013242.","journal-title":"Eur J Pharmacol"},{"key":"77_CR41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/0006-291X(92)92331-Q","volume":"189","author":"Y Uchida","year":"1992","unstructured":"Uchida Y, Ninomiya H, Sakamoto T, et al.: ET-1 released histamine from guinea pig pulmonary but not peritoneal mast cells. Biochem Biophys Res Commun 1992, 189:1196\u20131201.","journal-title":"Biochem Biophys Res Commun"},{"key":"77_CR42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.1992.tb04011.x","volume":"33","author":"SD Brain","year":"1992","unstructured":"Brain SD, Thomas G, Crossman DC, et al.: Endothelin-1 induces a histamine-dependent flare in vivo, but does not activate human skin mast cells in vitro. Br J Clin Pharmacol 1992, 33:117\u2013120.","journal-title":"Br J Clin Pharmacol"},{"key":"77_CR43","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/01.HYP.21.6.752","volume":"21","author":"TF L\u00fcscher","year":"1993","unstructured":"L\u00fcscher TF, Seo BG, B\u00fchler FR: Potential role of endothelin in hypertension: controversy of endothelin in hypertension. Hypertension 1993, 21:752\u2013757.","journal-title":"Hypertension"},{"key":"77_CR44","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1161\/01.HYP.21.6.747","volume":"21","author":"PM Vanhoutte","year":"1993","unstructured":"Vanhoutte PM: Is endothelin involved in the pathogenesis o hypertension? Hypertension 1993, 21:747\u2013751.","journal-title":"Hypertension"},{"key":"77_CR45","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","volume":"267","author":"OF Wagner","year":"1992","unstructured":"Wagner OF, Christ G, Wojta J, et al.: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992, 267:16066\u201316068.","journal-title":"J Biol Chem"},{"key":"77_CR46","doi-asserted-by":"crossref","first-page":"55 59","DOI":"10.1111\/j.1365-2362.1992.tb01936.x","volume":"22","author":"H Vierhapper","year":"1992","unstructured":"Vierhapper H, Wagner OF, Nowotny P, Waldh\u00e4usl W: Effect of endothelin-1 in man: pretreatment with nifedipine, with indomethacin and with cyclosporine A. Eur J Clin Invest 1992, 22:55 59.","journal-title":"Eur J Clin Invest"},{"key":"77_CR47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7326\/0003-4819-114-3-213","volume":"114","author":"K Yokokawa","year":"1991","unstructured":"Yokokawa K, Tahara H, Kohno M, et al.: Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 1991, 114:213\u2013215.","journal-title":"Ann Intern Med"},{"key":"77_CR48","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI117470","volume":"94","author":"WG Haynes","year":"1994","unstructured":"Haynes WG, Hand MF, Johnstone HA, et al.: Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994, 94:1359\u20131364.","journal-title":"J Clin Invest"},{"key":"77_CR49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0024-3205(93)90233-S","volume":"52","author":"M Nishikibe","year":"1993","unstructured":"Nishikibe M, Tsuchida S, Okada M, et al.: Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 1993, 52:717\u2013724.","journal-title":"Life Sci"},{"key":"77_CR50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/01.HYP.25.4.501","volume":"25","author":"B Seo","year":"1995","unstructured":"Seo B, L\u00fcscher TF: ETA and ETB receptors mediate contraction to endothelin-1 in renal artery of aging SHR. Effects of FR139317 and bosentan. Hypertension 1995, 25:501\u2013506.","journal-title":"Hypertension"},{"key":"77_CR51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.HYP.31.1.499","volume":"31","author":"M Barton","year":"1998","unstructured":"Barton M, d\u2019Uscio LV, Shaw S, et al.: ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31:499\u2013504. The authors investigated the involvement of ET in vascular alteration in salt-induced Dahl rat hypertension and sugests that ET-1 acts as a local mediator of vascular dysfunction and hypertrophy.","journal-title":"Hypertension"},{"key":"77_CR52","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1161\/01.CIR.93.5.866","volume":"93","author":"G Noll","year":"1996","unstructured":"Noll G, Wenzel RR, Schneider M, et al.: Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996, 93:866\u2013869. This study shows that in contrast to offspring of normotensives, in normotensive offspring of hypertensives, mental stress, but not hypoxia, induces parallel increases in sympathetic nervous system activity and plasma endothelin.","journal-title":"Circulation"},{"key":"77_CR53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension: bosentan hypertension investigators. N Engl J Med 1998, 338:784\u2013790. The first chronic study with a mixed ET antagonist (bosentan) in human essential hypertension. It shows dose-dependent antihypertensive effects of bosentan in 293 patients similar to 10 mg of enalapril.","journal-title":"N Engl J Med"},{"key":"77_CR54","first-page":"S88","volume":"16","author":"RR Wenzel","year":"1998","unstructured":"Wenzel RR, Fleisch M, Shaw S, et al.: Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. J Hypert 1998, 16:S88 [Abstract].","journal-title":"J Hypert"},{"key":"77_CR55","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1161\/01.CIR.98.21.2235","volume":"98","author":"RR Wenzel","year":"1998","unstructured":"Wenzel RR, Fleisch M, Shaw S, et al.: Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998, 98:2235\u20132240. The first study with a mixed ET-antagonist (bosentan) in CAD patients assessing systemic and coronary hemodynamics. Bosentan reduces systolic blood pressure and improves coronary blood flow, especially in patients with low plasma-low-density lipoprotein cholesterol levels.","journal-title":"Circulation"},{"key":"77_CR56","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM199110033251404","volume":"325","author":"A Lerman","year":"1991","unstructured":"Lerman A, Edwards BS, Hallett JW, et al.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991, 325:997\u20131001.","journal-title":"N Engl J Med"},{"key":"77_CR57","first-page":"H339","volume":"257","author":"D Ezra","year":"1989","unstructured":"Ezra D, Goldstein RE, Czaja JF, Feuerstein GZ: Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol 1989, 257:H339\u2013343.","journal-title":"Am J Physiol"},{"key":"77_CR58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.RES.74.1.105","volume":"74","author":"JR Teerlink","year":"1994","unstructured":"Teerlink JR, Breu V, Sprecher U, et al.: Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 1994, 74:105\u2013114.","journal-title":"Circ Res"},{"key":"77_CR59","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1097\/00005344-199100177-00055","volume":"17","author":"Y Hattori","year":"1991","unstructured":"Hattori Y, Nakaya H, Endo M, Kanno M: Pharmacological analysis of the positive inotropic effect of endothelin-1 in guinea pig left atria. J Cardiovasc Pharmacol 1991, 17:S194\u2013196.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0006-291X(89)92397-8","volume":"159","author":"CS Moravec","year":"1989","unstructured":"Moravec CS, Reynolds EE, Stewart RW, Bond M: Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun 1989, 159:14\u201318.","journal-title":"Biochem Biophys Res Commun"},{"key":"77_CR61","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI118092","volume":"96","author":"H Fujisaki","year":"1995","unstructured":"Fujisaki H, Ito H, Hirata Y, et al.: Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995, 96:1059\u20131065.","journal-title":"J Clin Invest"},{"key":"77_CR62","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/cvr\/27.12.2125","volume":"27","author":"LC Katwa","year":"1993","unstructured":"Katwa LC, Guarda E, Weber KT: Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 1993, 27:2125\u20132129.","journal-title":"Cardiovasc Res"},{"key":"77_CR63","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/cvr\/27.12.2130","volume":"27","author":"E Guarda","year":"1993","unstructured":"Guarda E, Katwa LC, Myers PR, et al.: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993, 27:2130\u20132134.","journal-title":"Cardiovasc Res"},{"key":"77_CR64","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/cvr\/27.9.1613","volume":"27","author":"GJ Grover","year":"1993","unstructured":"Grover GJ, Dzwonczyk S, Parham CS: The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993, 27:1613\u20131618.","journal-title":"Cardiovasc Res"},{"key":"77_CR65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.CIR.91.4.941","volume":"91","author":"AM Zeiher","year":"1995","unstructured":"Zeiher AM, Goebel H, Schachinger V, Ihling C: Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995, 91:941\u2013947.","journal-title":"Circulation"},{"key":"77_CR66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00005344-199601000-00023","volume":"27","author":"PH Dagassan","year":"1996","unstructured":"Dagassan PH, Breu V, Clozel M, et al.: Up-Regulation of Endothelin-B Receptors in Atherosclerotic Human Coronary Arteries. J Cardiovasc Pharmacol 1996, 27:147\u2013153.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0735-1097(10)80214-1","volume":"18","author":"DJ Stewart","year":"1991","unstructured":"Stewart DJ, Kubac G, Costello KB, Cernacek P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991, 18:38\u201343.","journal-title":"J Am Coll Cardiol"},{"key":"77_CR68","first-page":"1070","volume":"70","author":"P Lechleitner","year":"1992","unstructured":"Lechleitner P, Genser N, Mair J, et al.: Endothelin-1 in patients with complicated and uncomplicated myocardial infarction. Clin Invest 1992, 70:1070\u20131072.","journal-title":"Clin Invest"},{"key":"77_CR69","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/01.CIR.89.4.1573","volume":"89","author":"T Omland","year":"1994","unstructured":"Omland T, Terje Lie R, Aakvaag A, et al.: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994, 89:1573\u20131579.","journal-title":"Circulation"},{"key":"77_CR70","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/01.CIR.82.6.2226","volume":"82","author":"KB Margulies","year":"1990","unstructured":"Margulies KB, Hildebrand FJ, Lerman A, et al.: Increased endothelin in experimental heart failure. Circulation 1990, 82:2226\u20132230.","journal-title":"Circulation"},{"key":"77_CR71","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1161\/01.CIR.90.5.2510","volume":"90","author":"JR Teerlink","year":"1994","unstructured":"Teerlink JR, Loffler BM, Hess P, et al.: Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994 90:2510\u20132518.","journal-title":"Circulation"},{"key":"77_CR72","first-page":"H868","volume":"275","author":"E Oie","year":"1998","unstructured":"Oie E, Bjonerheim R, Grogaard HK, et al.: ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats [in process citation]. Am J Physiol 1998, 275:H868\u2013877.","journal-title":"Am J Physiol"},{"key":"77_CR73","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(12)60795-2","volume":"67","author":"RJ Rodeheffer","year":"1992","unstructured":"Rodeheffer RJ, Lerman A, Heublein DM, Burnett JJ: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992, 67:719\u2013724.","journal-title":"Mayo Clin Proc"},{"key":"77_CR74","doi-asserted-by":"crossref","first-page":"732 736","DOI":"10.1016\/S0140-6736(95)91504-4","volume":"346","author":"W Kiowski","year":"1995","unstructured":"Kiowski W, Sutsch G, Hunziker P, et al.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732 736.","journal-title":"Lancet"},{"key":"77_CR75","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1097\/00005344-199322008-00079","volume":"22","author":"P Roubert","year":"1993","unstructured":"Roubert P, Cornet S, Plas P, et al.: Upregulation of renal endothelin receptors in glycerol-induced acute renal failure in the rat. J Cardiovasc Pharmacol 1993, 22:S303\u2013305.","journal-title":"J Cardiovasc Pharmacol"},{"key":"77_CR76","doi-asserted-by":"crossref","first-page":"418 422","DOI":"10.1093\/ndt\/5.6.418","volume":"5","author":"AN Warrens","year":"1990","unstructured":"Warrens AN, Cassidy MJ, Takahashi K, et al.: Endothelin in renal failure. Nephrol Dial Transplant 1990, 5:418 422.","journal-title":"Nephrol Dial Transplant"},{"key":"77_CR77","first-page":"345","volume":"264","author":"P Nambi","year":"1993","unstructured":"Nambi P, Pullen M, Jugus M, Gellai M: Rat kidney endothelin receptors in ischemia-induced acute renal failure. J Pharmacol Exp The 1993, 264:345\u2013348.","journal-title":"J Pharmacol Exp The"},{"key":"77_CR78","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000187212","volume":"63","author":"F Mallamaci","year":"1993","unstructured":"Mallamaci F, Parlongo S, Zoccali C: Influence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure. Nephron 1993, 63:291\u2013295.","journal-title":"Nephron"},{"key":"77_CR79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0006-291X(90)91456-3","volume":"169","author":"F Fyhrquist","year":"1990","unstructured":"Fyhrquist F, Saijonmaa O, Metsarinne K, et al.: Raised plasma endothelin-I concentration following cold pressor test. Biochem Biophys Res Commun 1990, 169:217\u2013221.","journal-title":"Biochem Biophys Res Commun"},{"key":"77_CR80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1681\/ASN.V3158","volume":"3","author":"SN Heyman","year":"1992","unstructured":"Heyman SN, Clark BA, Kaiser N, et al.: Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992, 3:58\u201365.","journal-title":"J Am Soc Nephrol"},{"key":"77_CR81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/29.1.69","volume":"29","author":"SN Heyman","year":"1992","unstructured":"Heyman SN, Clark BA, Kaiser et al.: In-vivo and in-vitro studies on the effect of amphotericin B on endothelin release. J Antimicrob Chemother 1992, 29:69\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"77_CR82","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00004424-199304000-00011","volume":"28","author":"SN Heyman","year":"1993","unstructured":"Heyman SN, Clark BA, Cantley L, et al.: Effects of ioversol versus iothalamate on endothelin release and radiocontras nephropathy. Invest Radiol 1993, 28:313\u2013318.","journal-title":"Invest Radiol"},{"key":"77_CR83","doi-asserted-by":"crossref","first-page":"1391 1392","DOI":"10.1001\/jama.1991.03460110057019","volume":"265","author":"K Ohta","year":"1991","unstructured":"Ohta K, Hirata Y, Shichiri M, et al.: Cisplatin-induced urinary endothelin excretion [letter]. JAMA 1991, 265:1391 1392.","journal-title":"JAMA"},{"key":"77_CR84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.1993.53","volume":"43","author":"S Orisio","year":"1993","unstructured":"Orisio S, Benigni A, Bruzzi I, et al.: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993, 43:354\u2013358.","journal-title":"Kidney Int"},{"key":"77_CR85","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ki.1993.263","volume":"44","author":"A Benigni","year":"1993","unstructured":"Benigni A, Zoja C, Corna D, et al.: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993, 44:440\u2013444.","journal-title":"Kidney Int"},{"key":"77_CR86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000139096","volume":"47","author":"S Vemulapalli","year":"1993","unstructured":"Vemulapalli S, Chiu PJ, Chintala M, Bernardino V: Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology 1993, 47:188\u2013193.","journal-title":"Pharmacology"},{"key":"77_CR87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-2999(92)90774-X","volume":"221","author":"N Mino","year":"1992","unstructured":"Mino N, Kobayashi M, Nakajima A, et al.: Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 1992, 221:77\u201383.","journal-title":"Eur J Pharmacol"},{"key":"77_CR88","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1172\/JCI117046","volume":"93","author":"M Gellai","year":"1994","unstructured":"Gellai M, Jugus M, Fletcher et al.: Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J Clin Invest 1994, 93:900\u2013906.","journal-title":"J Clin Invest"},{"key":"77_CR89","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/365759a0","volume":"365","author":"M Clozel","year":"1993","unstructured":"Clozel M, Breu V, Burri K, et al.: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993, 365:759\u2013761.","journal-title":"Nature"},{"key":"77_CR90","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1148\/radiology.196.3.7644626","volume":"196","author":"SD Oldroyd","year":"1995","unstructured":"Oldroyd SD, Haylor JL, Morcos SK: Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 1995, 196:661\u2013665.","journal-title":"Radiology"},{"key":"77_CR91","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1152\/jappl.1996.81.4.1510","volume":"81","author":"J Dupuis","year":"1996","unstructured":"Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996, 81:1510\u20131515.","journal-title":"J Appl Physiol"},{"key":"77_CR92","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.CIR.94.7.1578","volume":"94","author":"J Dupuis","year":"1996","unstructured":"Dupuis J, Stewart DJ, Cernacek P, Gosselin G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94:1578\u20131584.","journal-title":"Circulation"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-999-0077-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-999-0077-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-999-0077-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T18:04:35Z","timestamp":1737050675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-999-0077-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1007\/s11906-999-0077-7","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"type":"print","value":"1522-6417"},{"type":"electronic","value":"1534-3111"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}